Business
Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort
The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints NEW
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints \nNEW YORK, May 3, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the preliminary findings from Hoth's randomized, double-blind, placebo-controlled Phase 1b study investigating the safety and efficacy of BioLexa Lotion in patients with mild to moderate atopic dermatitis. The study is being conducted at multiple sites in Australia by the contract research organization Novotech. Currently, Novotech has reported no adverse events from those that have completed the BioLexa dosing period.\n\n \n \n \n \n \n \n\n \nThe company reported findings from three efficacy secondary endpoints from the trial: the Eczema Area and Severity Index (EASI), the SCORing Atopic Dermatitis scale (SCORAD), and an Investigator Global Assessment scale (IGA). The study is randomized to 3 blinded treatments at a ratio of 40% BioLexa:40% Active Control Lotion:20% Placebo Lotion. Of the patients that have completed the dosing period with the blinded, investigative product, some patients have shown improvement across the EASI, SCORAD, and IGA; this improvement in AD symptoms and severity was also observed at the 1-week follow-up visit. Some patients were considered \"almost clear\" at the end of the dosing period and \"clear\" or \"almost clear\" at the 1-week follow-up based on the IGA score.\nThe full study results remain blinded and will be shared at a later date, as they become available.\nAbout Hoth Therapeutics, Inc.\nHoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer's Disease, atopic dermatitis and other indications. To learn more, please visit https://ir.hoththerapeutics.com/.\nForward-Looking Statement\nThis press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995...